BioRestorative Therapies, Inc.
BRTXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, BioRestorative Therapies, Inc. focuses on Biotechnology services and products. BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The $2.2M market capitalization puts BRTX squarely in micro-cap range for its industry. The company develops programs related to the treatment of disc/spine disease and metabolic disorders.
Market Cap
$2.2M
Beta
0.85
P/E (TTM)
—
P/E (Fwd)
-0.16
EPS (TTM)
$-21.49
EPS (Fwd)
$-10.40
ROE
-241.1%
ROA
-118.8%
Cash
$3.6M
Total Debt
$28,774
Free CF
-$9.7M
52W Change
-94.9%
Annual Financials
Cash vs Debt
Where BRTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BRTX finished 102.53% above its 150-day moving average ($0.79) and 107.79% above its 200-day moving average ($0.77). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BRTX overbought or oversold?
At the October 20, 2026 close, BRTX's RSI(14) was 22.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
BioRestorative Therapies, Inc. holds $3.6M in cash against $29K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$9.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -241.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $120K (2022) to $360K (2025), reflecting a 200% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing BRTX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.